Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV trial on serological cross-reactivity after Qdenga dengue vaccination in Swedish travelers
2025-520655-92-00Phase 4Authorised
- Sponsor
- Region Vaesterbotten, Umea University
- Start
- May 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dengue tetravalent vaccine, live, attenuated in dengue fever, sponsored by Region Vaesterbotten, Umea University. Planned start May 2025; status: authorised.
02
Drugs
dengue tetravalent vaccine, live, attenuated
03
Conditions
dengue fever
Beyond the preview
Go deeper on 2025-520655-92-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520655-92-00.